

Ionis and Roche report positive Phase 3 IMAgINATION trial interim results for sefaxersen in treating primary IgA nephropathy.
You can purchase shares of Ionis Pharmaceuticals (NASDAQ:IONS) through any online brokerage.
Other companies in Ionis Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Ionis Pharmaceuticals has a consensus price target of $86.78.
The stock price for Ionis Pharmaceuticals (NASDAQ: IONS) is $42.8738 last updated October 26, 2026 at 6:38 PM EDT.
There are no upcoming dividends for Ionis Pharmaceuticals.
Ionis Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Ionis Pharmaceuticals.
Ionis Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological,...